Galapagos NV (GLPG)
NASDAQ: GLPG · Real-Time Price · USD
34.00
+0.07 (0.21%)
Feb 11, 2026, 12:55 PM EST - Market open
Galapagos NV Employees
Galapagos NV had 558 employees as of June 30, 2025. The number of employees decreased by 146 or -20.74% since the number was reported on December 31, 2024.
Employees
558
Change
-146
Growth
-20.74%
Revenue / Employee
$603,303
Profits / Employee
-$916,674
Market Cap
2.22B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 558 | -146 | -20.74% |
| Dec 31, 2024 | 704 | -419 | -37.31% |
| Dec 31, 2023 | 1,123 | -215 | -16.07% |
| Dec 31, 2022 | 1,338 | 29 | 2.22% |
| Dec 31, 2021 | 1,309 | -180 | -12.09% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,869 |
| Ultragenyx Pharmaceutical | 1,294 |
| Recursion Pharmaceuticals | 800 |
| Ascentage Pharma Group International | 605 |
| Harmony Biosciences Holdings | 268 |
| Soleno Therapeutics | 152 |
| Mesoblast | 81 |
| Dianthus Therapeutics | 78 |
GLPG News
- 5 weeks ago - Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities - GlobeNewsWire
- 7 weeks ago - Galapagos: Pivoting From Clinical Risk To Strategic Capital Allocation - Seeking Alpha
- 2 months ago - Galapagos Presented New ATALANTA-1 Cell Therapy Data in MCL at ASH 2025 - GlobeNewsWire
- 2 months ago - Galapagos Receives Transparency Notifications from Bank of America - GlobeNewsWire
- 3 months ago - Galapagos NV (GLPG) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Galapagos to Present New Data from Cell Therapy Program at ASH 2025 - GlobeNewsWire
- 3 months ago - Galapagos to Present In Vitro Data at ACR Convergence 2025 Suggesting Differentiation of GLPG3667 from Other TYK2 Inhibitors - GlobeNewsWire
- 4 months ago - Biotech firm Galapagos to wind down cell therapy business - Reuters